Form 4: Guardant Health CPO Sells Shares Under 10b5-1 Plan

Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 10,031 shares of common stock under a pre-arranged trading plan.

Summary

• Terilyn J. Monroe, Chief People Officer of Guardant Health, Inc. (GH), reported the sale of common stock.
• A total of 10,031 shares were sold across three separate transactions on January 7, 2026.
• The sales were executed at weighted average prices of $111.7521, $112.6182, and $113.4397 per share.
• These transactions were conducted pursuant to a Rule 10b5-1(c) trading plan, indicating they were pre-scheduled.
• Following these sales, Ms. Monroe beneficially owns 20,990 shares of Guardant Health common stock.

Sentiment

Score: 4

Explanation: While insider selling can be viewed negatively by the market, the execution under a pre-arranged 10b5-1 plan mitigates some of the negative sentiment, suggesting personal financial planning rather than a lack of confidence in the company's future. However, it still represents a reduction in insider ownership.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not necessarily a reaction to recent, unexpected events or a change in the insider's outlook on the company.

Negatives

• An insider, the Chief People Officer, sold a significant number of shares (10,031 shares), reducing their direct beneficial ownership.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a signal of reduced confidence or that the stock price may be nearing a peak, potentially leading to negative short-term sentiment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Insider sales are a routine part of executive compensation and personal financial planning, particularly when executed under pre-arranged 10b5-1 plans, which aim to mitigate concerns about trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially influencing short-term trading sentiment, though the context of a 10b5-1 plan is important for a balanced view.

Key Dates

Recommendation

The insider sale, while notable, was conducted under a pre-arranged 10b5-1 plan, which typically indicates personal financial planning rather than a change in the insider's view of the company's prospects. Without additional information on the company's fundamentals or other market factors, this single transaction does not warrant a change from a 'hold' position. Investors should monitor future insider activity and company performance.

Keywords

Guardant Health, GH, Insider Trading, Form 4, Stock Sale, Terilyn J. Monroe, Chief People Officer, 10b5-1 Plan